I

Integer Holdings Corporation

Medical device CDMO for cardiac devices

Engineer 2 - Labeling

Full-TimeUpdated on 10/23/2026
$69.8k - $102.3k+ Cash-based incentive program
Mid
Bachelor's
Remote in USA
Remote
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a related field or at least 3 years of experience with GMP, FDA, and change control processes.
  • Strong written and oral communication skills.
  • Strong attention to detail.
  • Strong organizational and time management abilities.
  • Ability to work in a team environment.
  • Strong understanding of the regulatory labeling landscape.
  • Strong proficiency with Microsoft Office.
  • Strong proficiency with Adobe InDesign.
  • Strong proficiency with Adobe Illustrator.
  • Knowledge and understanding of label creation software.
Responsibilities
  • Adhere to Integer’s values and all safety, environmental, security, and quality requirements, including Quality Management Systems, Safety, Environmental and Security Management Systems, U.S. Food and Drug Administration regulations, company policies and operating procedures, and other regulatory requirements.
  • Plan, schedule, conduct, and coordinate detailed phases of the labeling process within part of a major project or a total project of moderate scope.
  • Prepare, create, and control labels and Instructions for Use according to procedure, including updating these documents throughout the product life cycle; track and maintain labeling documents using process tools for revision control.
  • Review labeling documents for accuracy and ensure text and graphics formatting conform to established guidelines for consistency, technical construction, and overall presentation.
  • Initiate and/or implement change control requests related to labeling updates, follow through on open requests, and evaluate the impact assessment related to updates.
  • Upload and maintain applicable UDI databases, including FDA UDI GUDID and EUDAMED.
  • Investigate, contribute to, and support new labeling process technologies of moderate scope.
  • Prepare necessary paperwork and documentation for projects undertaken.
  • Strive for continuous improvement and consistency in deliverables.
  • Communicate with internal and external customers regarding ongoing labeling updates.
  • Execute new labeling in support of new product development and current production; collaborate with cross-functional teams to ensure labeling deliverables are on track for each project.
  • Prepare and manage labeling translation activities.
  • Collaborate with cross-functional teams to review product specifications and evaluate product characteristics, special-handling and safety requirements, and materials required for labeling development.
  • Support execution of Packaging and Label Validation Plans and Reports.
  • Ensure packaging and labeling comply with regulatory, customer, specification requirements, and standards; support internal and external regulatory submission packages.
  • Support validation of packaging and labeling equipment, including IQ, OQ, and PQ.
  • Support Value Stream manufacturing teams on packaging and labeling projects.
  • Provide technical support for label printing and database management.
  • Perform other duties as required.

About the company

I

Integer Holdings Corporation

View

Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Wilmington, Delaware

Founded

1940

Get referred to Integer Holdings Corporation

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
  • Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
  • KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.

What critics are saying

  • Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
  • Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
  • Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.

What makes Integer Holdings Corporation unique

  • Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
  • Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
  • KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Adoption Assistance
  • Parental Leave
  • 401(k) Company Match
  • 401(k) Retirement Plan
  • Paid Vacation
  • Paid Holidays

Growth & Insights and Company News

6 month growth

0%

1 year growth

-2%

2 year growth

-1%
Ticker Report
Aug 29th, 2026
Boussard & Gavaudan Gestion Sas Makes New $2.60 Million Investment in Integer Holdings Corporation $ITGR

Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]

Yahoo Finance
Aug 16th, 2026
Healthcare stocks outpace S&P 500 by 13 percentage points over six months

Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.

Yahoo Finance
Aug 4th, 2026
Integer Holdings acquired by KKR for $5.7B in all-cash deal at $127 per share

Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.

BizWire Express
Aug 3rd, 2026
KKR to acquire Integer for $5.7B in all-cash deal at $127 per share

KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.

Yahoo Finance
Aug 3rd, 2026
Integer Holdings beats Q2 expectations with $464M revenue and $1.60 earnings per share

Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.